Novo Nordisk AS's investigational once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide is poised to give Eli Lilly & Co.'s once-weekly GLP-1 Trulicity a run for its money after demonstrating better performance for blood sugar lowering and weight loss in the head-to-head SUSTAIN 7 study of type 2 diabetes.
Semaglutide, which like Trulicity (dulaglutide) is given by injection, is now under review at the US FDA, with a December...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?